Buy-Side M&A
GeneWorx Capital has developed an expansive, proprietary database of small companies, institutional labs and university research scientists with cutting edge, life science IP and know-how. We can draw from this database and the rich ecosystem from which it is drawn to conduct targeted searches to meet your strategic goals such as:
- Fill out a drug development pipeline with promising new assets
- Complement/expand your offerings/development with enabling new tools and platforms
- Extend your reach into new customer footprints and geographies by acquiring complementary businesses
- Elevate shareholder value by growth through acquisition
Sell-Side M&A
GeneWorx Capital positions you with large, strategic and synergistic acquirers to achieve M&A exits at maximum “strategic” valuations.
As former “buying executives” for M&A deals at many large technology companies, GeneWorx Capital partners have unique insights into the thought processes of acquiring executives and paths for catalyzing strategic deals. Our experience enables us to position your company for maximum exit valuation by highlighting technology and positioning business and market synergies in the most compelling way to potential acquirers.
We’ve been involved in dozens of high-value M&A exits of deep technology companies including sales of pre-revenue companies at valuations over $500M. Our goal is to create multi-bidder M&A situations, resulting in high transaction price based on the strategic value of the company’s business and technology, not simply as a multiple of EBITDA.